[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neonatal\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neonatal":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,46,73,108,150,177],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100639038","generating-intervals-of-reference-ffor-early-life-brain-biomarkers-100639038",false,"NCT07585149","Generating Intervals of Reference FFor Early Life Brain Biomarkers.","GIRAFFE","Inclusion Criteria:\n\n* Term neonate (≥37 weeks)\n* Planned routine venous blood drawn within one week of life\n* Relevant demographic\u002Fclinical information available, including gestational age, day of life, birth weight, sex, race, mode of delivery, and 5-minute Apgar score\n* Informed parental consent obtained prior to any study procedures\n\nExclusion Criteria:\n\n* Pre-term neonates \\\u003C37 weeks\n* Any clinical evidence of neurological\u002F CNS abnormalities.\n* NICU admission\n* Any neonates with Suspected or culture-positive sepsis or meningitis Any known inborn errors of metabolism (IEM). Any known chromosomal abnormalities or any apparent congenital abnormalities\n* When the relevant demographic\u002Fclinical information is not available.",true,"ALL","0 Days","7 Days",{"count":21,"type":22},150,"ESTIMATED","OBSERVATIONAL","Highly sensitive immunoassays for the detection of neuro-specific biomarkers are becoming more accessible. Currently, the majority of these biomarkers are detected with the use of labour-intensive and highly skilled wet lab work. However, recent advancements have allowed for the introduction of these neuro-specific biomarkers into mainstream clinical chemistry analysers, bringing them closer to clinical care. There is a vast amount of published literature for neuro-specific biomarkers in an adult and ageing population, unfortunately, the same cannot be said for the neonatal population. From the limited available literature, clear differences are being documented in physiological levels of neuro-specific biomarkers in adults and infants. Neuro-specific biomarkers such as GFAP (Glial Fibrillary Acidic Protein) and Tau are demonstrating promise for the early detection and prediction of neuro-developmental disorders. There is a need for an understanding of physiological levels of these neuro-specific biomarkers in a neonatal population before they can be fully adopted into clinical routine. The development of a neonatal reference interval for neuro-specific biomarkers may provide a foundation for the accurate interpretation of neuro-specific biomarker elevations in neonatal brain injury, aiding in the development of biomarker-based screening tools for early diagnosis and intervention.",[26,27,28],"Reference Intervals","Biomarker in Early Diagnosis","Neonatal",[30,31,28,32],"Neurospecific","Biomarker","Reference Interval","RECRUITING","2026-05-08",{"date":36,"type":37},"2026-05-13","ACTUAL",{"date":39,"type":37},"2026-04-13",{"date":41,"type":22},"2027-06-30",{"name":43,"class":44},"University College Cork","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100607592","against-chikungunya-virus-and-neonatal-infection-100607592","NCT07190560","Against Chikungunya Virus and Neonatal Infection","ConvictionCHIK","Inclusion Criteria:\n\n* Treatment group\n\nNewborn:\n\n* whose mother has a clinical and\u002For laboratory diagnosis of Chikungunya (CHIK) infection occurring between 2 days before and 2 days after birth.\n* Hospitalized in a Level III neonatology unit in Mayotte or at the University Hospital of La Réunion.\n* Eligible for experimental treatment (called PC-CHIK-V):\n\n  * If the maternal infection was diagnosed between2 days before and the day of delivery, treatment can be administered within the first 12 hours of the newborn's life.\n  * If the maternal infection was diagnosed between 1 day and 2 days after birth, treatment can be administered within 12 hours of diagnosis.\n* Whose holders of parental authority have given free, informed, and written consent prior to any examination required for the research. Parallel Cohort of\n\nUntreated Newborns (parallel observational cohort)\n\nNewborns:\n\n* Whose mother has a clinical and\u002For laboratory diagnosis of CHIK-V infection occurring between 2 days before and 2 days after birth.\n* Hospitalized in a Level III neonatology unit in Mayotte or at the University Hospital of La Réunion.\n* Not treated with PC-CHIK-V:\n* Monitored in one of the units of the Neonatology Department for at least 5 days from the day of birth.\n* Whose holders of parental authority (or the holder if the mother is the sole holder of parental authority) have been informed of the research and have not objected to the use of data collected during hospitalization for research purposes.\n\nExclusion Criteria:\n\n* Newborns who present at birth with clinical criteria for ahypoxic-ischemic encephalopathy (HIE) that require therapeutic hypothermia according to the national protocol for \"neonatal therapeutic hypothermia\"\n* Newborns who require phototherapy treatment at the time of enrollment using devices with a maximum energy wavelength less than 425 nm and\u002For with an emission bandwidth with a lower limit of \\\u003C375 nm.","2 Days",{"count":55,"type":22},60,"INTERVENTIONAL",[58],"NA","The goal of this clinical trial is to learn if administration of plasma, from a whole blood donation from an individual who has declared a Chikungunya infection for less than 6 months , to a newborn, whose mother has a peripartum chikungunya infection, will have an impact on the proportion of newborns surviving without encephalitis\u002Fencephalopathy (EE) within the first 5 days of life. Researchers will compare results to an observational study of 30 newborns who couldn't have been proposed to participate at the clinical trial, because of delay of diagnosis or delay of transfer to hospital which doesn't allow transfusion or parents not accepting plasma transfusion to the newborn.\n\nParticipants of the clinical trial will:\n\n* receive a transfusion,\n* visit the clinic and undergo biological tests every day until day 7 and once between 1 and 3 months.\n\nParticipant of observational study as part of their regular medical care, and biological data will be reused for the research from the mother's diagnosis until the newborn reaches 3 months of age",[61,28,62,63],"Chikungunya Virus Infection","Transfusion","Encephalopathy","2026-05-04",{"date":34,"type":37},{"date":67,"type":22},"2026-08-01",{"date":69,"type":22},"2027-12-01",{"name":71,"class":44},"Centre Hospitalier Universitaire de la Réunion",2,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":16,"sex":17,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":56,"phases":84,"briefSummary":85,"conditions":86,"keywords":93,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":107},"100568106","neonatal-platelet-transfusion-threshold-trial-100568106","NCT06676904","Neonatal Platelet Transfusion Threshold Trial","NeoPlaTT","Inclusion Criteria:\n\n* Gestational age of 23 0\u002F7 to 26 6\u002F7 weeks\n* Postnatal age of \\\u003C 48 hours\n\nExclusion Criteria:\n\n* Comfort care or withdrawal of care planned\n* Neonatal alloimmune thrombocytopenia or suspected\u002Fconfirmed congenital platelet or bleeding disorder\n* Receipt of platelet transfusion\n* No receipt of Vitamin K\n* Parents\u002Fguardian decline consent","1 Hour","48 Hours",{"count":83,"type":22},2433,[58],"The objective of the NeoPlaTT trial is to test whether, among extremely preterm infants born at 23 0\u002F7 to 26 6\u002F7 weeks' gestation, a lower platelet transfusion threshold, compared to a higher threshold, improves survival without major or severe bleeding up to 40 0\u002F7 weeks' postmenstrual age (PMA).",[87,28,88,89,90,91,92],"Thrombocytopenia","Platelet Transfusion","Infant, Newborn, Diseases","Infant, Extremely Low Birth Weight","Infant, Small for Gestational Age","Thrombosis",[94,95,96],"platelet transfusion","neonatal","thrombosis","2026-03-24",{"date":99,"type":37},"2026-03-25",{"date":101,"type":37},"2025-06-13",{"date":103,"type":22},"2031-04-30",{"name":105,"class":106},"NICHD Neonatal Research Network","NETWORK",20,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":16,"sex":115,"minAge":116,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":56,"phases":119,"briefSummary":120,"conditions":121,"keywords":132,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":45},"100619990","mindfulness-and-meditation-based-lactation-education-on-maternal-breastmilk-in-the-neonatal-icu-100619990","NCT07351799","Mindfulness and Meditation Based Lactation Education on Maternal Breastmilk in the Neonatal ICU","The Impact of Mindfulness and Meditation Based Lactation Education on Maternal Breastmilk in the Neonatal ICU: Intervention Study","Inclusion Criteria:\n\n* Maternal age \\> 20 years of age\n* Read, write and understand English\n* Infant NICU admit\n* Infant birthplace of Rochester, MN (Mayo Clinic)\n* Maternal adherence to pumping ≥ 8 times in 24 hours\n* Mother enrolled within 72 hours of birth\n* Gestational age of neonate at birth of \\\u003C 34 0\u002F7 weeks\n\nExclusion Criteria:\n\n* Maternal extensive existing mindfulness practice\n* Maternal breast\u002Fchest surgery\n* Maternal polycystic ovarian syndrome (PCOS)\n* Maternal current illicit substance abuse\n* Diagnosis of maternal current severe mental health concerns\n* Maternal multiple gestation (twins or higher order) pregnancy and delivery","FEMALE","20 Years",{"count":118,"type":22},40,[58],"The purpose of this research is to investigate associations between mindfulness and meditation techniques and changes in maternal breastmilk in the mother pumping for her NICU infant.",[122,123,124,125,28,126,127,128,129,130,131],"Lactation","Mindfulness","NICU","Breastmilk","Meditation","Pumping, Breast","Cortisol","Oxytocin","Anxiety","Depression",[133,134,124,135,28,136,137,138,139,140,131],"lactation","mindfulness","breastmilk","meditation","pumping, breast","cortisol","oxytocin","anxiety","2026-01-12",{"date":143,"type":37},"2026-01-20",{"date":145,"type":37},"2025-09-22",{"date":147,"type":22},"2026-11-02",{"name":149,"class":44},"Mayo Clinic",{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":17,"minAge":158,"maxAge":159,"enrollmentInfo":160,"targetDuration":162,"studyType":23,"phases":4,"briefSummary":163,"conditions":164,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":45},"100606973","turkish-version-of-the-hammersmith-neonatal-neurological-examination-hnne-100606973","NCT07182513","Turkish Version of the Hammersmith Neonatal Neurological Examination (HNNE)","Turkish Version of the Hammersmith Neonatal Neurological Examination (HNNE) With High-Risk of Infants: A Study of Validity and Reliability","HNNE","Inclusion Criteria:\n\n1. Infants with periventricular hemorrhage, intracranial hemorrhage grades 2, 3, or 4, cystic periventricular leukomalacia (PVL), stage 3 hypoxic ischemic encephalopathy, neonatal bilirubin encephalopathy (kernicterus), perinatal stroke, perinatal asphyxia, and hydrocephalus.\n2. Infants with chronic lung disease, respiratory lung disease (RDS), bronchopulmonary dysplasia (BPD), and long-term oxygen supplementation.\n3. Preterm infants with sepsis due to gram-negative bacteria, necrotizing enterocolitis (NEC), and infantile apnea.\n4. Preterm infants with a low 5-minute Apgar score (3 or below), diagnosed with intrauterine growth restriction, multiple births (twins, triplets), and preterm infants with Retinopathy of Prematurity (ROP).\n5. Infants with prolonged severe hypoglycemia and hypocalcemia.\n6. Babies who are small for gestational age (SGA), less than the 3rd percentile, or large for gestational age (LGA), greater than the 97th percentile.\n7. Babies receiving mechanical ventilation for more than 24 hours.\n8. Babies born at less than 32 weeks' gestation and weighing less than 1500 grams.\n\nExclusion Criteria:\n\n1. Babies with congenital malformations (spina bifida, congenital muscular torticollis, arthrogryposis multiplex congenita, etc.)\n2. Babies diagnosed with metabolic and genetic diseases (Down syndrome, spinal muscular atrophy, Duchenne muscular dystrophy, etc.)\n3. Babies still intubated and mechanically ventilated at 3 months postterm","37 Weeks","42 Weeks",{"count":161,"type":22},120,"1 Day","High-risk infants are defined as an infant with a history of adverse environmental and biological factors that may lead to neuromotor developmental problems. This group includes premature babies born at less than 37 weeks, term babies with low birth weight (LBW), or babies with developmental delays due to various reasons. These babies are also monitored for cerebral palsy (CP). CP is the most common physical disability in childhood, with an incidence of 2.1 per 1000 births. CP encompasses a group of permanent impairments in movement and posture development resulting from injury to the developing brain. Thanks to preventive measures and advances in obstetric and neonatal care, the incidence and severity of CP are currently decreasing in some countries, and it is emphasized that recovery can be more rapid with the use of early diagnosis guidelines or protocols in follow-up units. Early detection and monitoring of infants in the community for CP is essential only with appropriate, valid, and reliable tools to minimize potential sequelae through the timely implementation of CP-specific interventions. International guidelines require monitoring of infants at high risk of CP. This follow-up should be conducted by an interdisciplinary team, including a neonatologist, pediatrician, pediatric neurologist, pediatric physiotherapist, speech-language-swallowing therapist, and special education specialist. Pediatric physiotherapists are an important part of this team for developmental follow-up and rehabilitation. The Hammersmith Neonatal Neurological Examination (HNNE) is a method developed by Dubowitz and used in both clinical and research neurological examinations of preterm and term infants, is the neonatal form of the Hammersmith Infant Neurological Examination (HINE). Its use in the Neonatal Intensive Care Unit (NICU) is crucial for beginning risk assessment as early as possible. Research has determined the optimality score for this test for term infants evaluated in the first days after birth. Subsequently, the current version of the HNNE was standardized by evaluating low-risk term and high-risk preterm infants (25-34 weeks) at term ages, 6-48 hours after birth.The aim of this study was to develop a Turkish version of the HNNE for high-risk infants in Turkey and determine its validity and reliability. The translated HNNE version, which was found to be valid and reliable in this population, will be suitable for use by all healthcare professionals in Turkey. This study also aimed to determine the predictive value of HNNE at corrected 3-4\u002F6 and 12 months when used in the follow-up of at-risk infants in NICUs in Turkey.The study consists of two phases. The first phase consisted of translating the short version of the survey into Turkish and conducting its cultural adaptation. The second phase involved reliability analysis. The principles of Guillemin et al. and Beaton et al. will be used in the translation and cultural adaptation processes.",[165,166,167,28],"Cerebral Palsy (CP)","Infant ALL","Neurological Development","2025-09-18",{"date":170,"type":37},"2025-09-19",{"date":172,"type":37},"2025-08-22",{"date":174,"type":22},"2026-03-15",{"name":176,"class":44},"Kahramanmaras Sutcu Imam University",{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":185,"enrollmentInfo":186,"targetDuration":4,"studyType":56,"phases":188,"briefSummary":190,"conditions":191,"keywords":193,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":45},"100600849","phase-2-comparison-of-zinc-and-probiotics-on-neonates-with-indirect-hyperbilirubinemia-undergoing-phototherapy-100600849","NCT07102836","COMPARISON OF ZINC AND PROBIOTICS ON NEONATES WITH INDIRECT HYPERBILIRUBINEMIA UNDERGOING PHOTOTHERAPY","COMPARATIVE EFFECTS OF ZINC AND PROBIOTICS ON NEONATAL INDIRECT HYPERBILIRUBINEMIA UNDERGOING PHOTOTHERAPY","ZIPP","Inclusion Criteria:\n\n* 1\\. Term or Near term neonates 2. Age \\\u003C7 days at enrollment 3. Bilirubin levels within phototherapy range according to NICE bilirubin threshold charts 4. No identifiable pathology 5. Tolerating oral feeds 6. Parental or Guardian written informed consent taken.\n\nExclusion Criteria:\n\n* 1\\. Positive sepsis screen or clinical signs of infection 2. Direct hyperbilirubinemia 3. Gastrointestinal malformations 4. Oral intolerance 5. Requiring mechanical ventilation 6. Congenital anomalies 7. Parental or Guardian refusal to participate in study","28 Days",{"count":187,"type":22},110,[189],"PHASE2","Study will evaluate effects of oral zinc and probiotics supplementation in neonates who have indirect hyperbilirubinemia and are receiving phototherapy. Aim is to compare efficacy of these two drugs in clearing bilirubin and reducing duration of phototherapy. Neonates will be randomly assigned to receive either drug alongside phototherapy.",[192,28],"Indirect Hyperbilirubinemia",[194,195,196,197,198,199,200,201,192],"Zinc","Probiotics","Jaundice","Phototherapy","Neonates","Randomized Controlled Trial","Bilirubin","Enterohepatic Circulation","2025-07-30",{"date":204,"type":37},"2025-08-05",{"date":206,"type":22},"2025-08-07",{"date":208,"type":22},"2026-05-07",{"name":210,"class":44},"Quaid-e-Azam Medical College"]